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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a very common lethal monogenetic disease with significant morbidities and a
high likelihood of progression to renal failure for which there is no proven disease-specific therapy currently available for clinical use. Human
ADPKD cystic epithelia have proliferative abnormalities mediated by EGFR over-expression and mispolarization leading autocrine response to
EGF family ligands. We now show that apical localization of EGFR complexes in normal fetal and ADPKD epithelia is associated with
heterodimerization of EGFR(HER-1) with HER-2(neu/ErbB2), while basal membrane localization in normal adult renal epithelia is associated
with EGFR(HER-1) homodimers. Since ADPKD epithelial cells have reduced migratory function, this was used as a bioassay to evaluate the
ability of compounds to rescue the aberrant human ADPKD phenotype. General tyrosine kinase inhibition by herbimycin and specific inhibition
of HER-2(neu/ErbB2) by AG825 or pretreatment with ErbB2 siRNA reversed the migration defect of ADPKD epithelia. Selective inhibition of
EGFR(HER-1) showed partial rescue. Increased ADPKD cell migration after inhibition of p38MAP kinase but not of PI3-kinase implicated
p38MAPK downstream of HER-2(neu/ErbB2) stimulation. Daily administration of AG825 to PKD1 null heterozygous mice significantly
inhibited the development of renal cysts. These studies implicate HER2(neu/ErbB2) as an effector of apical EGFR complex mispolarization and
that its inhibition should be considered a candidate for clinical therapy of ADPKD.
© 2006 Elsevier B.V. All rights reserved.Keywords: EGF receptor; Polarity; Signal transduction; Renal development; Small molecule therapy; Tyrosine kinase; Dimerization; PKD null mouse; siRNA1. Introduction
Polycystic Kidney Disease (PKD) is a group of diseases
caused by mutations in single genes [1]. The most common and
clinically significant of these is ADPKD, a progressive cystic
disease leading to endstage renal failure that is estimated to
affect 10 million patients world-wide. Although there has been a
significant increase in our understanding of the basic biology of
ADPKD in recent years, this has not yet been translated into an
effective therapy to delay the onset or reduce the rate of decline
of renal function in these patients. Although renal cysts may
develop in utero [2], it is their subsequent expansion to occupy
>66% of the grossly enlarged kidney that leads to the onset of⁎ Corresponding author. Tel.: +1 212 659 9383; fax: +1 212 849 2434.
E-mail address: pat.wilson@mssm.edu (P.D. Wilson).
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doi:10.1016/j.bbadis.2006.04.006renal functional decline, hypertension and other associated
symptoms which do not usually occur until adulthood and
typically in the 4th or 5th decade. The progressive nature of this
disease and the ability of the kidney to function adequately with
>30% normal renal parenchyma presents a substantial window
of opportunity to treat by retardation of cystic expansion.
The cell biology of cyst expansion in ADPKD is understood
to involve a combination of hyper-proliferation and fluid
secretion in every segment of the nephron that is brought
about in part, by defects in the polarized distribution and
function of epithelial membrane proteins including the epidermal
growth factor receptor (EGFR) and the sodium pump, as well as
cAMP-dependent chloride transport [3–5]. Apical mislocaliza-
tion, over-expression and hyperactivity of the EGFR protein
complex, coupled with apical secretion of EGF and related
ligands into cyst lumens, has been shown to create an autocrine/
paracrine proliferative loop in human ADPKD epithelia in vivo
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autosomal recessive (AR)PKD [3,4,6] (Fig. 1). Importantly,
EGFR receptor blockade, restriction of bioligand availability or
genetic crosses with waved mice (deficient in EGFR) have been
shown to have beneficial effects in mice with ARPKD [7–9]. In
addition mice transgenic for activated EGFR or for Her-2(neu-
erbB2) develop renal cystic disease [10]. EGFR (HER-1)
belongs to a larger family of molecules of which there are 4
known members: HER (neu/ErbB) 1, 2, 3 and 4 that are capable
of homo- and hetero-dimerization, regulation and modulation by
several ligands and cross-talk between heterologous signaling
pathways [11,12]. In addition to essential roles as mediators of
cell proliferation and differentiation in development, increased
levels and activation of EGFR(HER-1) or HER-2(neu/ErbB2)
have been reported in several human malignancies including
those of the breast, pancreas, lung, head and neck, colon,
prostate, stomach and ovaries, and the kidney and predicts an
aggressive course of disease and poor prognosis [13,14].
Since we had previously demonstrated that ADPKD is often
associated with the failure to down-regulate fetal genes
including Pax-2, WT-1 and the β2 subunit of NaK-ATPase
[15,16], that the mispolarization defects of NaK-ATPase are dueFig. 1. Schematic of EGF Receptor-mediated cystic expansion in ADPKD kidneys.
membranes. (B) ADPKD cystic epithelia have apical EGF Receptor complexes and
heterodimers are localized on apical cell membranes of normal fetal and ADPKD cy
normal adult renal tubule epithelia.to the persistent expression of the fetal form (α1β2) of NaK-
ATPase [17,18]; and that abnormal molecular species of EGFR-
like proteins are present in ADPKD kidney tissues [3], the
present studies sought to determine whether the aberrant apical
localization of the EGFR complex seen in ADPKD cystic
epithelia was due to the persistent expression and heterodimer-
ization of EGFR (HER-1) with a fetal isoform. This was
confirmed by the cloning and localization of ErbB2 in ADPKD
and fetal renal epithelial cells as well as by co-immunoprecip-
itation analyses. The importance of ErbB2 as a potential
therapeutic target for ADPKD was further suggested since its
inhibition by small molecule or siRNA treatment restored
normal migratory function to human ADPKD epithelia in an in
vitro assay and retarded renal cyst formation in PKD null mice.
2. Methods
2.1. Tissues and cells
Normal kidneys were procured by National Disease Research Interchange
(Philadelphia, PA). Only kidneys without disease that had not been subjected to
warm ischemia prior to being flushed with Collins salts solution at 4 °C were
selected. These kidneys had been prepared for transplantation but rejected for(A) Normal renal tubule epithelia have EGF Receptor complexes on basal cell
secrete EGF apically into the lumen. (C) EGFR(HER-1)/HER-2 (neu/ErbB2)
stic epithelia. EGFR(HER-1) homodimers are localized on basal membranes of
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surgical removal prior to transplantation.
Primary cell strains were derived by microdissection of normal human adult
kidney collecting tubules and cyst-lining epithelia from ADPKD kidneys
attachment and growth on type I collagen in 1% serum-containing fully defined
supplemented media [19,20]. Conditionally immortalized (CI) normal and
ADPKD cell lines were derived from primary cultures of individually
microdissected collecting tubules and ADPKD cyst epithelia by retroviral
transduction of neomycin-resistance and temperature sensitive T antigen, into
monolayers during the exponential phase of growth followed by selection for
6 weeks in Geneticin [21] and dilution cloning. Functional and marker analysis
have previously shown that these cultured lines attain maximal differentiated
properties after 5–13 days at 37 °C [20]. Clones that recapitulated the EGFR
(HER-1) and HER-2 (neu/ErbB2) protein expression and distribution patterns
seen in vivo most closely were selected for use in these studies.
Wild-type (+/+) and heterozygous (+/−) PKD1 null mice [22] were
identified by genomic PCR and 4 groups of 5 animals each were allowed to
develop normally for up to 4 months. Test agents were added to the drinking
water of the mice from 6 weeks of age. None had an effect on the amounts of
water drunk by the mice. One group of +/− mice received the highly selective
ErbB2 inhibitor, AG825 (50 μM, Calbiochem); one group of +/− mice received
DMSO vehicle (1:1000); while one group of +/− and one group of +/+ mice had
no additives in their drinking water. MRI analysis was carried out 4 weeks prior
to sacrifice when kidneys were removed and quantitative histo-pathological
analysis of 4% paraformaldehyde fixed kidneys stained with hematoxylin and
eosin was carried out. Whole kidneys (n=10 in each group) were embedded, and
10×1 mm, evenly spaced slices were obtained by vibratome sectioning
throughout the kidney. After re-embedding, 10×5 μM sections were obtained
from each slice (n=100 sections per kidney) for quantitative analysis of tubule
diameters. Digital images of non-overlapping (571×428 μm) fields were taken
for each section. A counting grid with 8000 μm2 squares was overlaid and every
eighth square was analyzed for tubule diameter using Image J—Grid Plugin
(rsb.info.nih.gov/ij).
2.2. RT-PCR degenerate cloning of Her2(neu/ErbB2)
1024× degenerate 17-mer sense and 512× degenerate 17-mer antisense
primers were designed against conserved regions of the tyrosine kinase domain
of EGFR family proteins aligned using the UWGCG Pileup program and were
used to screen a human fetal kidney library. Multiple cDNA clones of the EGF
receptor homolog HER-2(neu/ErbB2) were obtained from human fetal and
ADPKD kidney.
2.3. Immunohistochemistry
Tissueswere sliced and fixed at source for 4 h at 4 °C in 4%paraformaldehyde
in Phosphate Buffered Saline (PBS), dehydrated and embedded in low
temperature paraffin prior to sectioning at 5 μm. Monolayer cell cultures were
fixed in 4% paraformaldehyde in PBS for 10 min. Immunolocalization was
carried out using an indirect avidin–biotin-enhanced technique (Vectastain,
Vector Laboratories) and aminoethylcarbazole detection yielding a red reaction
product (Vector). For each experiment, control sections were incubated in
identical conditions but in the absence of primary antibody. No staining was seen
(data not shown). Anti-EGF receptor (Transduction Labs) and anti-ErbB2
(Neomarkers) antibodies were selected after screening for mono-specificity by
Western blot (below) and absence of non-specific staining.
2.4. Immunoblot and immunoprecipitation
Cells were grown to confluence and fully differentiated and polarized prior
to washing 3 times in cold PBS containing a broad spectrum protease inhibitor
cocktail. Triton X100/NP40 extracts were subjected to polyacrylamide gel
electrophoresis and transferred to PVP membranes for immunoblot analysis
using anti-EGFR (1:1000, Transduction Labs) and anti-ErbB2 (1:1000,
Neomarkers) antibodies and visualization by enhanced chemiluminescence.
Equal amounts of protein were loaded per lane as, determined by a Bradford
protein assay. This was also verified by blotting with anti-actin (Sigma, 1:4000).All antibodies were selected for their mono-specificity and recognized a single
band of predicted molecular weight. Additional sets of cell extracts were
subjected to immuno-precipitation with anti-EGFR and Erb-B2/ Sepharose A/G
(Oncogene Research Products) prior to immuno-blot analysis with anti-EGFR
and anti-ErbB2.
2.5. Migration assays
A modified Boyden chamber assay was developed (schematized in Fig. 5).
Differentiated (5 days at 37 °C) ADPKD and age matched normal renal epithelia
are rendered fluorescent by incubation with fluorescent calcein-AM (Molecular
Probes). 5000 or 10,000 cells were plated per well in quadruplicate into 24 well
plates Fluroblock membrane assemblies (HTS-Falcon). Cells were seeded in the
upper chamber and allowed to attach for 4 h in cell-type-specific media
containing 1% serum in each chamber. Inserts were then transferred to wells
containing 1% serum in the upper chamber and 5% serum in the lower chamber
to provide a serum gradient (see schema) and baseline fluorescence was read.
Fluorescence, which can only be detected in the lower chambers of these
assemblies, was measured at several time-points over a 24–36 h period using a
microfluorimetric plate reader.
2.5.1. Cell treatments
Prior to experiments, all compounds were tested for a 2-day period over a
concentration range to determine the optimal dose: herbimycin (1 μM, Sigma);
okadaic acid (1 μM, Tocris), sodium vanadate (25 μM, Sigma), AG825 (50 μM,
Calbiochem), AG1478 (100 μM, Calbiochem), A25 (25 μM, Calbiochem) and
B42 (50 μM, Calbiochem), SB203580 (25 μM, Tocris), UO126 (50 μM, Tocris),
Wortmannin (100 nM, Sigma), EGF (100 ng /ml, Amgen) and Heregulin
(25 ng/ml, R&D Systems).
2.5.2. siRNA ErbB2
Specific and non-targeting, scrambled siRNA (100 nM, Dharmacon) were
transfected into ADPKD epithelia using Lipofectamine 2000 (Invitrogen)
according the manufacturer's instructions. Cells were collected 24 h after
transfection and used for migration assays and Western immunoblot analysis.
2.5.3. Statistics
Data were collected and plotted as mean±standard error and analysis of
variance carried out to compare the effect of additive versus untreated ADPKD
value at each time point (*). Statistical analysis was performed using Graphpad
InStat software (San Diego, CA. www.graphpad.com).3. Results
3.1. HER-2(neu/ErbB2) is highly expressed in ADPKD and
normal fetal kidneys
In addition to EGFR (HER-1), degenerate PCR isolated many
clones that when sequenced were identified as HER-2(neu/
ErbB2) (supplementary data). Antibody screening by Western
immunoblot and immunohistochemical analysis showed that
while EGFR(HER-1) was expressed in normal fetal, normal
adult and ADPKD kidneys (Fig. 2A–C), HER-2(neu/ErbB2)
was expressed in normal fetal and ADPKD kidneys but none
was detected in normal adult kidneys (Fig. 2D–F).
3.2. HER-2(neu/ErbB2 is localized at the apical
plasma-membranes of ADPKD and normal fetal renal epithelia
Immunohistochemical analysis showed that the EGFR
(HER-1) in normal adult kidneys was associated with the
basolateral membranes of proximal and distal tubule segments
Fig. 2. Immunohistochemistry and immunoblot analysis of human renal kidneys. (A) Normal human fetal kidney, 19-week gestation. EGFR localization on
the apical membranes of ureteric bud-derived, collecting tubule epithelium. (B) Normal adult kidney, 40 years old. EGFR localization on the basal
membranes of proximal tubule epithelia. (C) ADPKD cyst with apical localization of EGFR. (D) Normal human fetal kidney, 19-week gestation. HER-2
(neu/ErbB2) localization on the apical membranes of ureteric bud-derived, collecting tubule epithelium. (E) Normal adult kidney, 40 years old. No HER-2
(neu/ErbB2) detected in proximal tubules, loops of Henle or collecting tubules. (F) ADPKD cyst with apical localization of HER-2 (neu/ErbB2). All
tissues were dissected and fixed for 4 h at 4 °C in 4% paraformaldehyde in PBS immediately after flushing with Collins salts solution at 4 °C,
embedded in low temperature paraffin and sectioned at 5 μm prior to avidin–biotin-enhanced immunohistochemistry using aminoethylcarbazole as (red)
color reaction product (Vector). Right panel: Western immunoblot of EGFR and HER-2(neu/ErbB2) in normal Human Fetal Kidney (HFK); Normal adult
Human Kidney (NHK) and ADPKD kidney tissue. Anti-EGFR 1:1000 (Transduction Labs), denoted by arrow in upper panel; anti-ErbB2 1:1000
(Neomarkers), denoted by arrow in lower panel; anti-actin 1:4000 (Sigma), denoted by asterisk in upper and lower panels. Equal amounts of protein were
loaded per lane.
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kidneys, both EGFR and HER-2/neu were localized at the
apical plasma-membranes of cyst lining epithelia and fetal
ureteric bud-derived collecting tubules, respectively (Fig. 2A,
C, D, F). This suggested that the persistent expression of
renal HER-2(neu/ErbB2) after birth was associated with the
apical distribution of the EGFR complex in ADPKD epithelia
that leads to receptor complex accessibility to apical EGF
ligand and increased proliferation.
3.3. EGFR(HER1) and HER2(neu/ErbB2) heterodimerize in
ADPKD and fetal epithelia
To prevent contamination from non-epithelial cell types,
characterized differentiated clonal human renal epithelial cell
lines were used that recapitulated the patterns of EGFR and
HER-2(neu/ErbB2) expression seen in vivo. Western immuno-
blot analysis detected EGFR (HER-1) in normal fetal, normal
adult and ADPKD cells and HER-2(neu/ ErbB2) in normal fetal
and ADPKD cells only (Fig. 3 right panel). Immunocytochem-
istry confirmed apical distribution of EGFR and HER-2(neu/
ErbB2) in ADPKD and normal fetal epithelia but basolateral
staining for EGFR only in normal adult epithelia (Fig. 3A–F).
To determine the subunit composition of EGFR complexes in
these epithelia, Co-immunoprecipitation analysis showed that
EGFR(HER-1) co-associated with HER-2(neu/ErbB2) in
ADPKD and human fetal (HFCT) epithelia but no heterodimers
were detected in normal human adult tubule epithelia (NHCT)
(Fig. 4).3.4. Inhibition of HER-2(neu/ErbB2) rescues the abnormal
migratory defect of human ADPKD epithelia in vitro
ADPKD epithelia have been shown to exhibit many
alterations by comparison to age-matched normal renal tubular
epithelia, e.g., NHCT, including significantly impaired migra-
tion in response to growth factor gradients by comparison to
age-matched normal human renal epithelia (Fig. 5A). Since this
property is consistent between primary (1°) cultures from
different individuals and derived conditionally immortalized
(CI) cell lines, this phenotypic property provides a unique and
rapid screening assay to evaluate the effects of potential
modulators of the human ADPKD phenotype. Since previous
studies had implicated hyperactivity of the EGFR tyrosine
kinase as a mechanism for cyst enlargement [3,7], the effect of
the general tyrosine kinase inhibitor, Herbimycin was first
evaluated and shown to return the ADPKD migration curve to
normal (Fig. 5B). Protein tyrosine phosphatase inhibition by
okadaic acid or sodium vanadate, however, either had no effect
or further decreased ADPKD epithelial cell migration (Fig. 5B).
To determine the relative efficacies of EGFR antagonists, a
variety of compounds were compared. Of interest and
significance, the addition of a specific, selective inhibitor of
HER-2(neu/ErbB2), AG825 was shown to provide the most
effective rescue of the ADPKD migration defect (Fig. 5C). The
selective EGFR inhibitor AG1478 also provided significant
improvement while the tyrophostin EGFR inhibitors A25 and
B42, which show additional cross-reactivity against JAK2,
ERKs and phospho-FAK were less effective (Fig. 4C). No
Fig. 3. Immunocytochemistry and immunoblot analysis of human renal epithelia in vitro. (A) Normal human collecting tubule (HFCT) epithelia show punctate EGFR
localization on the apical membranes. (B) Basolateral, chickenwire pattern of distribution of EGFR in normal human adult renal epithelia (NHCT). (C) Punctate apical
localization of EGFR in human ADPKD epithelia. (D) Normal human fetal collecting tubule (HFCT) epithelia show punctate apical localization of HER-2 (neu/
ErbB2). (E) Normal adult NHCT epithelia. No HER-2 (neu/ErbB2) detected. (F) ADPKD cystic epithelia with punctate apical localization of HER-2 (neu/ErbB2)
Right panel: Western immunoblot of EGFR and HER-2(neu,ErbB2) in HFCT, NHCT and ADPKD epithelial cells. Antibodies and conditions were the same as
described in the legend to Fig. 2. (G) Confocal immunofluorescence of ADPKD monolayer culture, x–z plane: Primary antibody anti-EGFR, secondary Alexa-488
(green). (H) Confocal immunofluorescence of ADPKD monolayer culture, x–z plane: Primary antibody anti-ErbB2, secondary Alexa-568 (red).
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probably due to the lack of T antigen at 37 °C and the short
periods of exposure to the drugs. Further inhibitor analysis
suggested that the rescue of the ADPKD phenotype could be
mediated via the p38 MAP kinase pathway since the ADPKD
migration defect was rescued by its inhibitor SB203580 but not
after inhibition of MEK 1 and 2 by UO126 nor by inhibition of
the PI3 kinase pathway by Wortmannin (Fig. 5D). No additive
effect of AG825+SB203580 was observed (data not shown)
suggesting that maximal migration had already been reached
under the conditions of this assay. Finally, occupancy of the
EGFR/HER-2(neu/ErbB2) receptor dimer by EGF or Heregulin
ligands depressed ADPKD migration further (Fig. 4E) con-
firming a primary role for receptor occupancy and activation in
ADPKD cell aberrant function.
To further confirm the central role for HER-2(neu/erbB2) as a
mediator of ADPKD epithelial malfunction ADPKD epithelial
cells were treated with a specific ErbB2 siRNA which reducedErbB2 protein levels by approximately 70% (Fig. 6A). After 16
and 36 h, the siRNA-treated cells showed significantly increased
migration in response to growth factor gradient by comparison to
the control cells: 61±4.9 versus 45±3.7, P<0.05 and 91±7.3
versus 65±5.2, P<0.05, respectively (Fig. 6B). This further
confirms that reduction inErbB2expression leads torestorationof
normal phenotypic function to human ADPKD epithelial cells.
3.5. HER-2(neu/ErbB2) inhibition retards cyst formation in
PKD1 null mice
In addition to human cell based assays, it is important to test
the effects of potential therapeutic manipulations in relevant
mouse models of disease. For this evaluation the PKD1 null
mouse was selected, since in its heterozygous state renal
collecting tubule cysts are seen after 8 weeks of age (Fig. 7A),
closely mimicking human ADPKD. It had previously been
reported that EGFR is apically misolocalized in the cysts of
Fig. 4. (A) Immunoprecipitation of NHCT and ADPKD cells with EGFR and
HER-2(neu/ErbB2) followed by immuno-blotting with HER-2(neu/ErbB2)
antibody or EGFR antibody. Anti-EGFR 1: 1000 ( Transduction Labs); anti-
ErbB2 1: 1000 (Neomarkers). (B) Double immunofluorescence of anti-EGFR/
Alexa 488 (green) and anti-ErbB-2/Alexa 458 (red) in ADPKD monolayer.
Fig. 6. Rescue of ADPKD epithelial Migration defect by ErbB2 siRNA.
ADPKD CI epithelial cell lines were differentiated for 5 days at 37 °C then
transfected with specific and control (scrambled) siRNA for ErbB2 (100 nM,
24 h) using Lipofectamine 2000. (A) Western blot analysis of ErbB2 siRNA
versus control (scrambled) transfected cells. (B) Migration assay: 5000 ADPKD
cells plated per well; 9 replicates per measurement. Control cells (blue column)
versus siRNA treated ADPKD cells (red column). *P<0.05.
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confirmed ErbB2 expression in fetal and cystic+/−mice (Fig.
7C), an analogous situation to that seen in human kidneys
(compare with Fig. 2). Quantitative analysis of 10 kidneys from
5 mice each in 4 groups of normal (wild-type) and heterozygousFig. 5. Migration assays. Confluent cultures were dissociated with collagenase, cells
10,000 cells were plated per well in quadruplicate into 24 well plate Fluroblock memb
upper chamber and 5% serum in the lower chamber (see schema). Fluorescence, whic
over a 24 h period using a microfluorimetric plate reader. Prior to experiments, all co
the optimal dose. Data were collected and plotted as mean±standard error and ana
ADPKD values at each time point (* denotes statistical significance). (A) Prima
Collecting Tubules (NHCT) epithelia. (B) Treatment of ADPKD epithelia with He
tyrosine phosphatase inhibitors, okadaic acid (1 μM, Tocris) and sodium vanadate
Calbiochem) a specific inhibitor of HER-2(neu/ErbB2) versus AG1478 (100 μM,
(25 μM, Calbiochem) and B42 (50 μM, Calbiochem). (D) Treatment of ADPKD epith
(50 μM, Tocris) an inhibitor of MEK 1 and 2; and Wortmannin (100 nM, Sigma) a
(100 ng/ml, Amgen) and Heregulin (25 ng/ml, Biomeda) ligands.PKD1 null mice showed that treatment with AG825 reduced the
appearance and degree of cystic expansion of renal collecting
tubule cysts as determined by stereological measurement of
collecting tubule diameters (Fig. 7B). These measurements
reached statistical significance and represents a beneficial effect
in the very early stages of cyst formation in these mice. This
confirms that inhibition of ErbB2 results in therapeutic benefitcounted, washed and loaded with fluorescent calcein-AM (Molecular Probes).
rane assemblies (Falcon) in cell type-specific media containing 1% serum in the
h can only be detected in the lower chambers of these assemblies, was measured
mpounds were tested for a 2-day period over a concentration range to determine
lysis of variance carried out to compare the effect of addition versus untreated
ry (1°) versus Conditionally Immortalized (CI), age-matched Normal Human
rbimycin (1 μM, Sigma), a general tyrosine kinase inhibitor versus the protein
(25 μM, Sigma). (C) Treatment of ADPKD epithelia with AG825 (50 μM,
Calbiochem), a specific inhibitor of EGFR and less specific tyrophostins A25
elia with SB203580 (25 μM, Tocris), a p38 MAP kinase inhibitor versus UO126
specific inhibitor of PI3 kinase. (E) Treatment of ADPKD epithelia with EGF
Fig. 7. Retardation of cyst development in PKD1 null+/−mice by AG825
inhibition of ErbB2. Stereological quantitative analysis of randomized H&E
stained sections was carried out on 4 groups of 5 mice from 6 weeks to 4 months
of age. (A) H&E stained paraformaldehyde fixed section of wildtype (+/+)
PKD1 null mouse kidney at 16 weeks of age. (B) H&E stained paraformal-
dehyde fixed section of heterozygous (+/−) PKD1 null mouse kidney at
16 weeks of age. (C) Western immunoblot of EGFR and HER-2(neu/ErbB2) in
normal Mouse Fetal Kidney (MFK); Normal adult Mouse Kidney (NMK) and
PKD kidney tissue. Anti-EGFR: 1:1000 (Transduction Labs), denoted by arrow
in left panel; anti-ErbB2: 1: 1000 (Neomarkers), denoted by arrow in right panel;
anti-actin: 1:4000 (Sigma), denoted by asterisk. Equal amounts of protein were
loaded per lane. (D) Effects of administration of AG825, specific HER-2(neu/
Erb-B2) inhibitor, to PKD1+/− mice. Note statistically significant reduction in
cyst development compared to untreated +/− (*P<0.05) or DMSO vehicle-
treated +/− mice (#P<0.005).
653S.J. Wilson et al. / Biochimica et Biophysica Acta 1762 (2006) 647–655in a mouse model of ADPKD. Additional measurements of
body, heart and kidney weight ratios in treated +/− versus
untreated +/− and wildtype +/+ control mice did not show any
weight loss or adverse effects on behaviour in these mice (data
not shown).4. Discussion
Increased proliferation is an important component of cystic
expansion in ADPKD and is understood to be brought about, at
least in part, by the apical mislocalization of EGFR complexes
noted in cystic epithelia from human and numerous mouse and
other models of PKD [3,4,6,22].The EGFR family of receptors is comprised of 4 members.
Each protein is made up of an extracellular ligand binding
domain, a single transmembrane domain and an intracellular
portion containing the catalytic core and regulatory binding
sites. On binding of an appropriate ligand of the EGF family, the
membrane receptor molecules dimerize prior to activation by
autophosphorylation of specific tyrosine residues in the
intracellular domain. This creates binding sites for SH2 and
PTB-domain-containing effector and adaptor proteins and leads
to activation of the Ras/MAP kinase signaling pathway
followed by a proliferative response. Members of the EGFR
family frequently form heterodimers. EGFR/HER-2(neu/
ErbB2) heterodimerization has been shown to reduce EGFR
complex internalization by endocytosis [23] and thus contribute
to its hyperactivity. These properties have also been noted in
PKD epithelia [24].
Epithelial cell adhesion and migration are fundamental
components of the 3-dimensional morphogenesis during of
normal kidney development and differentiation. Inhibition of
PKD1-encoded polycystin-1 function during development
results in decreased migration and cystic dilation of
collecting tubules [25]. Apparently, these alterations in
epithelial cell behaviour are maintained since human and
mouse PKD cyst lining epithelia also show characteristically
increased adhesion and decreased directional migratory
responses.
Our studies show that HER-2 (neu/ErbB2) is highly
expressed in renal tubule epithelia of the normally developing
kidney as well as in ADPKD cyst lining epithelia. However,
no expression of HER-2(neu/Erb-B2) was seen in normal
adult kidneys. In addition, although the localization of EGFR
is restricted to the basolateral membranes of normal adult renal
tubule epithelia, EGFR and HER-2(neu/Erb-B2) were seen on
the apical plasma membranes of both normal fetal renal
tubules and ofADPKDcyst-lining epithelia. These observations
suggested that localization and activities of EGFR (HER-1) and
HER-2(neu/ErbB2) at specific polarized membranes of the
tubular epithelial cell surface are essential for normal renal
development and maintenance. In addition, these studies
suggested that the persistent expression of renal HER-2(neu/
ErbB2) after birthmight be associatedwith the apical distribution
of theEGFRcomplex inADPKDepithelia thatwould then lead to
EGFR/HER-2(neu/Erb-B2) complex accessibility to apical EGF
ligands and result in increased proliferation. Heterodimerization
of EGFR(HER-1) with HER-2(neu/Erb-B2) in normal fetal and
ADPKD epithelia was confirmed by co-immunoprecipitation
analysis.
Based on these observations that both HER-2(neu/ErbB2)
expression and heterodimerization with EGFR(HER-1) were
abnormal after birth in ADPKD and that its continued
expression was associated with the deleterious apical mis-
localization of functional EGFR complexes in ADPKD cysts,
HER-2(neu/ErbB2) inhibition was evaluated as a mediator of
rescue of the ADPKD cystic phenotype. ADPKD epithelia have
been shown to exhibit many alterations by comparison to
normal renal tubules including proliferation, secretion, adhesion
and migration ((1) for review). Using a robust cell-based
654 S.J. Wilson et al. / Biochimica et Biophysica Acta 1762 (2006) 647–655migration assay, in which human ADPKD epithelia migrate
through membranes orders of magnitude more poorly than
normal age-matched renal epithelia, in response to a growth
factor gradient, it was shown that specific inhibition of HER-2
(neu/Erb-B2) by small molecule (AG825) or specific siRNAwas
highly effective in restoration of normal migratory function.
Similar results with Herbimycin and SB203580 suggest that this
is due to its tyrosine kinase activity mediated via the p38 MAP
kinase pathway. Of interest, EGFR(HER-1)-specific inhibitors
were also partially effective, but less so when cross-reactive with
other intracellular pathways including JAK2,MEK/ERKs or PI3
kinase.
These results therefore implicate HER-2(neu/ErbB2) in
addition to EGFR (HER1) as a new target for therapeutic
retardation of cystic expansion in human ADPKD since normal
epithelial function can be restored to human ADPKD epithelial
cells in vitro. Importantly also, cystic development in
heterozygous PKD1 mutant mice was significantly reduced
by administration of the same HER-2(neu/Erb-B2) inhibitor to
their drinking water from 6 to 16 weeks. Since increased levels
of EGFR and/or HER-2 (neu/ErbB2) are characteristic of
several types of solid tumors including those of the breast, lung,
pancreas and kidney, this is already an active area of targeted
drug development and shows much promise. Both small
molecule inhibitor and antibody approaches have been used to
target these receptor signaling pathways including Herceptin
(Genentech-Roche), a humanized antibody recognizing the
extracellular domain of the HER-2(neu/ErbB2) receptor;
Erbitux (Imclone) a humanized antibody that binds the EGF
(HER-1); Tarceva (OSI-Genentech-Roche) and Iressa (Astra-
Zeneca) which inhibit EGFR tyrosine kinase activity. The
potential utility of specific tyrosine kinase inhibitor therapy has
recently been emphasized by the successful development of
Gleevec (Novartis) which inhibits intracellular signaling by the
mutant fusion protein Bcr-Abl non-receptor tyrosine kinase
found in chronic myelogenous leukemia [26]. Small molecule
therapies have the advantage of oral administration of one tablet
per day and of fewer, relatively minor side effects. The
availability of these FDA approved, so-called “smart drugs” that
specifically target HER-1/HER-2 receptor/ligand interactions,
tyrosine kinase activation or downstream signaling pathways
and their proven effectiveness in highly proliferative cancers
suggests a possibility that the same drugs might be effective at
lower daily doses in the HER-1/HER-2-mediated but less
proliferative condition of ADPKD. Since Iressa has been shown
to be most effective in those patients with a specific EGFR
mutation [27], it can also be speculated that different drugs
targeting EGFR/HER-2(neu/ErbB2) might be differentially
effective in specific patients depending on their specific disease
gene (PKD1, PKD2) mutation, or degree of dependence on
EGFR or HER-2(neu/ErbB2) activation.
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